Catalyst Pharmaceutical Partners (CPRX)
NASDAQ:CPRX
Want to see CPRX full AI Analyst Report?
CPRX Stock Chart & Stats
$26.26
-$0.35(-1.79%)
At close: 4:00 PM EST
$26.26
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $32.56
Previous CloseN/A
Volume328.11K
Average Volume (3M)2.74M
Market Cap
$3.84B
Enterprise Value$3.09B
Total Cash (Recent Filing)$755.86M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)17.5
Beta0.70
Next Earnings
Aug 12, 2026EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.80
Shares Outstanding122,419,770
10 Day Avg. Volume1,797,216
30 Day Avg. Volume2,736,847
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)2.99
Price to Sales (P/S)4.85
P/FCF Ratio13.68
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue5.18
Enterprise Value/Gross Profit6.29
Enterprise Value/Ebitda9.23
Forecast
1Y Price Target
$32.40Price Target Upside23.38% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)1.92
Revenue Forecast (FY)$634.19M
Bulls Say, Bears Say
Bulls Say
High Profit MarginsCatalyst’s very high TTM gross, EBITDA and net margins indicate durable pricing power in its rare-disease niche and a structurally profitable business model. Sustained margins support cash generation, reinvestment for patient programs, and resilience to reimbursement pressure over a multi-quarter horizon.
Conservative Balance SheetExtremely low leverage and a growing equity base provide long-term financial flexibility. This balance-sheet strength reduces insolvency risk, enables continued investment in commercialization or R&D, and gives optionality for bolt-on deals or to withstand temporary revenue volatility.
Extended Firdapse ExclusivityThe patent litigation settlement materially extends exclusivity visibility for Firdapse through 2035 if generics secure approval, preserving a core revenue stream. That structural protection supports predictable earnings and makes future cash flows more dependable for several years.
Bears Say
Revenue PlateauTop-line momentum has materially decelerated to near-flat TTM growth after rapid prior expansion. A stalled revenue trajectory reduces organic growth optionality, increases reliance on pricing or new launches, and pressures long-term EPS growth absent new product or market expansion.
Weakening FCF GrowthDespite strong absolute cash generation, recent negative free-cash-flow growth signals inconsistent cash expansion. This trend can constrain funding for pipeline investment, commercial support, or returns, and raises questions about the sustainability of current cash conversion trends.
Product Concentration RiskRevenue is concentrated in a small set of specialty drugs; FYCOMPA’s post-exclusivity decline underscores sensitivity to patent expiries and payer actions. High concentration makes company revenue and margin profiles vulnerable to single-product setbacks or competitive entry.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharmaceutical Partners’s price range in the past 12 months?
Catalyst Pharmaceutical Partners lowest stock price was $19.05 and its highest was $32.56 in the past 12 months.
What is Catalyst Pharmaceutical Partners’s market cap?
Catalyst Pharmaceutical Partners’s market cap is $3.84B.
When is Catalyst Pharmaceutical Partners’s upcoming earnings report date?
Catalyst Pharmaceutical Partners’s upcoming earnings report date is Aug 12, 2026 which is in 48 days.
How were Catalyst Pharmaceutical Partners’s earnings last quarter?
Catalyst Pharmaceutical Partners released its earnings results on May 11, 2026. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.475 by $0.025.
Is Catalyst Pharmaceutical Partners overvalued?
According to Wall Street analysts Catalyst Pharmaceutical Partners’s price is currently Undervalued.
Does Catalyst Pharmaceutical Partners pay dividends?
Catalyst Pharmaceutical Partners does not currently pay dividends.
What is Catalyst Pharmaceutical Partners’s EPS estimate?
Catalyst Pharmaceutical Partners’s EPS estimate is 0.48.
How many shares outstanding does Catalyst Pharmaceutical Partners have?
Catalyst Pharmaceutical Partners has 122,419,770 shares outstanding.
What happened to Catalyst Pharmaceutical Partners’s price movement after its last earnings report?
Catalyst Pharmaceutical Partners reported an EPS of $0.5 in its last earnings report, beating expectations of $0.475. Following the earnings report the stock price went down -0.032%.
Which hedge fund is a major shareholder of Catalyst Pharmaceutical Partners?
Currently, no hedge funds are holding shares in CPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.40 (23.38% Upside)
$32.40 (23.38% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 677.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.95%
12-Months-Change
Fundamentals
Return on Equity
23.65%
Trailing 12-Months
Asset Growth
26.27%
Trailing 12-Months
Company Description
Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
CPRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive performance narrative: strong double-digit revenue growth, record product and portfolio performance (notably FIRDAPSE and AGAMREE), robust profitability and cash generation, clear commercial execution improvements (patient identification, diagnostics, enrollment, and retention), and a constructive 2026 guidance range. Challenges were acknowledged—FYCOMPA's loss of exclusivity and revenue erosion, ongoing patent litigation, increasing royalties/milestones and gross-to-net pressure from IRA, and the need for additional label-supporting data for AGAMREE—all of which are being actively managed. On balance, highlights meaningfully outweigh the lowlights.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$32.40
▲(23.38% Upside)
Technical Analysis
Ownership Overview
5.52% Insiders
19.01% Mutual Funds
16.83% Other Institutional Investors
29.95% Public Companies and Individual Investors